Dan Hargrove, JD, LLM – CHIEF EXECUTIVE OFFICER
Mr. Hargrove, a lawyer by training, is a recognized expert and author on healthcare law and has extensive experience in operating oncology clinical trials. He has practiced and taught healthcare law for over 23 years with an expertise in the monetization and commercialization of intellectual property. He is the co-founder and Chief Development Officer for Cancer Insight, LLC, a drug development and clinical contract research organization. He is a former Air Force reserve judge advocate, holding the rank of Lieutenant Colonel, and a former professor of law at the US Army JAG School.
Carole Spangler Vaughn, PhD, MBA – CHIEF STRATEGY OFFICER
Dr. Carole Spangler Vaughn holds a Ph.D. in Biophysics from The Johns Hopkins University and an MBA from the University of Washington. She has held a variety of positions in the biopharma/healthcare industry, working for large and small companies, both in the laboratory and in business development. She spent several years as a laboratory manager at Bristol-Myers Squibb in their biologics discovery unit, mainly working on novel cancer biotherapeutics. She worked at the University of Washington’s Office of Technology Transfer, where she evaluated and out-licensed technologies. She was Director of Business Development at Dendreon Corporation, VP of Business Development for Clario Medical Imaging, and has consulted and advised several healthcare-related emerging companies, acting mainly in VP Business Development or CSO roles, focusing on strategy, fund-raising, sales, and marketing. She owned and operated the Hawaii State franchise for MediVet-America, the world’s largest veterinarian stem cell therapy company, where she trained clinics on four islands to isolate stromal vascular fraction from adipose, mainly to treat arthritis. Dr. Spangler Vaughn was an adjunct faculty member at Seattle Pacific University, teaching courses in their MBA program.
George Peoples, MD – CHIEF MEDICAL OFFICER
Dr. George Peoples is the founder and director of the Cancer Vaccine Development Program (CVDP), associated with the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, MD. He is the current CEO of Cancer Insight, LLC, Professor of Surgery at USUHS, and Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). He served as the past Chair of the Cancer Program, San Antonio Military Medical Center and the past Deputy Director of the United States Military Cancer Institute. He was the salutatorian graduate of the United States Military Academy and is a retired Army Colonel. Dr. Peoples is a graduate of Johns Hopkins Medical School, completed his surgical training at Harvard’s Brigham & Women’s Hospital, completed a postdoctoral fellowship at the Laboratory of Biological Cancer Therapy at Harvard Medical School, and completed a surgical oncology fellowship at MD Anderson. Dr. Peoples has published over 300 peer-reviewed articles and manuscripts and 12 book chapters on cancer, immune therapy, and similar subjects. He holds 7 INDs, 4 of his immunotherapies are in active commercial development, and he is the named inventor on dozens of patents in the field of immunotherapy.
Mark Horsey, MBA – CHIEF FINANCIAL OFFICER
Mr. Horsey has more than 20 years of broad international and domestic experience building financial and operational infrastructure for multi-national corporations in the biotech, information technology, and retail fields. He was formerly the Finance Director for Genzyme’s Multiple Sclerosis and Oncology Business Units and Controller for Dell Computer Company’s $14B North American Consumer Business Unit. Mr. Horsey has extensive knowledge of start-up finance and operational strategy.
Leon W. LeVan, PhD – CHEMISTRY MANUFACTURING AND CONTROLS
Dr. LeVan has over 25 years of pharmaceutical development experience in chemistry, manufacturing, and controls (“CMC”) and in drug metabolism. He was the former Director of Process Development at Genzyme Corporation supporting Genzyme’s oncology products. He held previous positions at Bone Care International, Inc. (acquired by Genzyme) and Hazleton Laboratories (now Covance). Dr. LeVan participated in the preparation of two successful NDAs and several sNDAs and INDs.
Shannon Kingman, MBA – INVESTOR AND PUBLIC RELATIONS
Ms. Kingman has over 10 years of experience in strategy, operations, analytics, and business development in the healthcare and life sciences industries. She was formerly Director of Strategy for Texas Health Resources hospital system, where she led numerous efforts to analyze and identify strategic opportunities for the network of over 20 hospitals. She previously worked as a management consultant within Accenture’s healthcare division, where she served clients in the life sciences, hospital, and payer industries.